Clinical trials: Anticoagulant
Healthy Volunteers
Pharmacogenomic Study on PKD/PKC of Dabigatran Etexilate and Rivaroxaban
The study will address the impact of genetical variation of a protein involved in the intestinal absorption of two new anticoagulants : Dabigatran etexilate and Rivaroxaban.
- Trial name
- DRIVING (NCT01627665)
- Testing
- D->R->C+R, D->R->C+D, R->D->C+D
- Where
- France
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Genital Haemorrhage
Genital Haemorrhage in Woman of Childbearing Age Treated for Venous Thromboembolism Disease : Comparison According to Oral Anticoagulant and Impact on Quality of Life
Little data are available on the genital haemorrhages in woman of childbearing age treated for venous thromboembolic disease by oral anticoagulant, especially the impact on the quality of life.
- Trial name
- GENB-OAB (NCT03772366)
- Where
- France
- Volunteers
- 453 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Atrial Fibrillation, Gerontology
Risk of Bleeding and Anticoagulation in Atrial Fibrillation: What Predictive Criterion Used?
Atrial fibrillation (AF) is a rhythmic cardiac activity disorder disturbing hemodynamic blood flow. It is a public health problem with 600,000 to 1 million people involved in France which 2/3 are aged over 75 years.
- Trial name
- PREDIC-AGE (NCT02858518)
- Testing
- questionnaires
- Where
- 5 sites in France
- Volunteers
- 120 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Solid Tumor, Cancer, Lung
Exploratory Drug Interaction Study Between SMIs and DOACs
The main objective of this study is to investigate the effect of small molecule inhibitors (SMIs), used in targeted therapy for tumours, on direct oral anticoagulants (DOACs).
- Trial name
- NCT05732350
- Where
- 2 sites in Netherlands
- Volunteers
- 37 people
- Sponsor
- Maastricht University Medical Center
Cancer, VTE (Venous Thromboembolism)
DOAC - Dosing Options in AntiCoagulation Prophylaxis
Blood clots, also known as venous thromboembolism (VTE), are a common and serious complication for people with cancer. They can lead to pain, hospitalizations, delayed cancer treatment, and even death.
- Trial name
- DOAC (NCT07005024)
- Testing
- Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation
- Where
- United States
- Volunteers
- 996 people
- Sponsor
- University of Vermont
Atrial Fibrillation
Global Anticoagulant Registry in the Field
The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF Registry) is a non-interventional, observational study that characterized a global population of non-valvular atrial fibrillation patients.
- Trial name
- GARFIELD-AF (NCT01090362)
- Where
- 35 sites in United States, Argentina and 33 more
- Volunteers
- 57,250 people
- Sponsor
- Thrombosis Research Institute
Atrial Fibrillation
This Study Observes the Use of New Oral Anticoagulants (NOACs) in Patients With a Heart Rhythm Disorder in Spain
The primary objective of the study is to describe the usage of NOACs in patients with NVAF, in the hospital setting, based on the baseline characteristics at the time of first NOAC initiation.
- Trial name
- RE-CONOCE (NCT03285373)
- Testing
- NOAC
- Where
- 75 sites in Spain
- Volunteers
- 1,008 people
- Sponsor
- Boehringer Ingelheim
Sinusoidal Obstruction Syndrome, Colorectal Liver Metastases
Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants
The purpose of the study is to determine whether anticoagulant use (i.e. salicylates, clopidogrel, low-molecular weight heparin, or coumarin derivates) is able to prevent the development of the sinusoidal obstruction syndrome…
- Trial name
- NCT00885950
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Maternal Complications After Oral Anticoagulation When Initiated Early and Late After Caesarean Section Done for Patients With Mechanical Heart Valve Prosthesis
Early Versus Late Post Caesarean Section Oral Anticoagulation Initiation and Risk of Maternal Complications in Patients With Mechanical Heart Valve Prosthesis
A randomized cohort study applied to patients with mechanical heart valve prosthesis who will be delivered by caesarean section at or after 28 weeks of gestation .
- Trial name
- NCT04855110
- Testing
- Warfarin Sodium started on Day 2 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant), Warfarin Sodium started on day 5 after caesarean section (in a dose that achieves a therapeutic level as indicated by the cardiology consultant)
- Where
- Egypt
- Volunteers
- 114 people
- Sponsor
- Cairo University
Atrial Fibrillation and Flutter
Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation
Background: The incidence of atrial fibrillation(AF) increases substantially with age and it is estimated that more than one third of AF patients are octogenarians.
- Trial name
- NCT02623049
- Testing
- New oral anticoagulant pharmacodynamic analysis (blood level assesment)
- Where
- 2 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Rabin Medical Center
Medication Adherence, Atrial Fibrillation (AF)
SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)
SNAP AF-52 is an ambidirectional observational registry conducted in family health centers (primary care) across Ordu, Türkiye, enrolling adults ≥65 years with a pre-existing diagnosis of atrial fibrillation.
- Conditions
- Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)
- Trial name
- SNAP AF-52 (NCT07242326)
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Kotyora Family Medicine Health Management and Education Association
Peripheral Arterial Disease
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
- Trial name
- NCT05009862
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81Mg Ec Tab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center
Left Sided Heart Failure, Left Ventricular Assist Device
Ventricular Assist Device Anti-Factor Xa (VAD ANTIX) Monitoring Study: a Prospective Randomized Feasibility Trial
This study evaluates two different methods for monitoring a patient's anti-clotting [heparin] therapy after they receive a heart pump implant [left ventricular assist device -LVAD].
- Conditions
- Left Sided Heart Failure, Left Ventricular Assist Device, Anticoagulant Therapy, Gastro Intestinal Bleeding
- Trial name
- VAD-ANTIX (NCT03143569)
- Testing
- aPTT guided heparin management, Anti-factor Xa guided heparin management
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Washington University School of Medicine
Arthroplasty, Replacement, Knee
Study to Evaluate Safety, PK and PD of Single and Multiple Ascending Doses of EP-7041 in Healthy Subjects
This First-In-Human study will evaluate the safety and tolerability, pharmacokinetic profile, and pharmacodynamic effects of EP-7041, a novel Factor XIa inhibitor, following IV administration of single ascending doses in healthy…
- Trial name
- NCT02914353
- Testing
- EP=7041
- Where
- Australia
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- eXIthera Pharmaceuticals
Extracorporeal Membrane Oxygenation Complication, Thrombosis
D-dimer to Improve Anticoagulation Outcome During ECMO loNg-term supporteD
This was a prospective, cohort study.
- Conditions
- Extracorporeal Membrane Oxygenation Complication, Thrombosis, Hemorrhage, Heparin Overdose
- Trial name
- DIAMOND (NCT03261284)
- Testing
- D-dimer-guided adjustment stratege, Thepeautic-heparin therapy
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Wuhan Asia Heart Hospital
Kawasaki Disease, Coronary Artery Aneurysm
Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years
Based on an established Kawasaki disease cohort database, this prospective, single-center, single-arm, observational study will collect clinical data from children aged 2 years and older with giant coronary artery aneurysms after…
- Conditions
- Kawasaki Disease, Coronary Artery Aneurysm, Rivaroxaban, Anticoagulant Drugs
- Trial name
- NCT06993636
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Children's Hospital of Fudan University
Non-Valvular Atrial Fibrillation
Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation
The primary objectives of this study are to compare the risk of major bleeding and stroke/systemic embolism (SE) events among oral anticoagulant (OAC)-naïve non-valvular atrial fibrillation (NVAF) patients initiating OAC warfarin…
- Trial name
- ARISTOPHANES (NCT03087487)
- Where
- United States
- Volunteers
- 466,991 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation
A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France
The purpose of this study is to look at how many patients with AF had strokes, major bleeding and death in both people who had and had not taken any oral anticoagulant.
- Trial name
- SIFNOS (NCT05838664)
- Testing
- No OAC, VKA, apixaban
- Where
- France
- Volunteers
- 2,140,403 people
- Sponsor
- Pfizer
Atrial Fibrillation
Study of DU-176b Aged 80 Years or Older
The purpose of this study is to evaluate the efficacy and safety of edoxaban in patients with non-valvular NVAF aged 80 years or older who are ineligible for available oral anticoagulation therapy.
- Trial name
- NCT02801669
- Testing
- Du-176b
- Where
- 164 sites in Japan
- Volunteers
- 984 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅰ (NCT06901466)
- Testing
- Experimental: Rivaroxaban monotherapy, Active Comparator: Rivaroxaban+Clopidogrel
- Where
- China
- Volunteers
- 880 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital